Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 354

Results For "ACC"

5624 News Found

Suburban Diagnostics unveils Reference Laboratory in Mumbai
Clinical Trials | January 09, 2023

Suburban Diagnostics unveils Reference Laboratory in Mumbai

The lab is also the first private lab in West India to have built its Mycobacteriology, Mycology, and Molecular Biology departments within a separate Bio Safety Level - 3 (BSL3) bio-containment lab


Dr. Mandaviya inaugurates Annex Building of ICMR-RMRC, Bhubaneswar
News | January 09, 2023

Dr. Mandaviya inaugurates Annex Building of ICMR-RMRC, Bhubaneswar

The centre has initiated next generation sequencing (NGS) as a tool for undertaking studies on genomic epidemiology of pathogens


Dabur India expects low to mid-single digit revenue growth for Q3 FY23
News | January 07, 2023

Dabur India expects low to mid-single digit revenue growth for Q3 FY23

International Business is expected to post double-digit revenue growth during the quarter in constant currency.


Zydus launches Topiramate Extended-Release Capsules
Drug Approval | January 07, 2023

Zydus launches Topiramate Extended-Release Capsules

Zydus is the first company to receive final approval and launch Topiramate Extended-Release Capsules, USP 25 mg, 50 mg, and 100 mg in the United States.


Alembic receives USFDA final approval for Fesoterodine Fumarate Extended-Release Tablets
Drug Approval | January 07, 2023

Alembic receives USFDA final approval for Fesoterodine Fumarate Extended-Release Tablets

Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, have an estimated market size of US$ 177 million for twelve months ending Sep 2022


Lupin launches novel fixed-dose triple drug combination DIFIZMA DPI to treat Asthma
News | January 06, 2023

Lupin launches novel fixed-dose triple drug combination DIFIZMA DPI to treat Asthma

The estimated national burden of asthma in India is at 17.23 million with an overall prevalence of 2.05% and out of this, approximately 30 lakh patients can be classified under “inadequately controlled”


Helix and QIAGEN to jointly develop and commercialize companion diagnostics for hereditary diseases
Clinical Trials | January 06, 2023

Helix and QIAGEN to jointly develop and commercialize companion diagnostics for hereditary diseases

Partnership to leverage the Helix Laboratory Platform and QIAGEN's biopharma relationships, NGS capabilities, and global regulatory expertise


Rupala to inaugurate 29 MVUs and centralised call center in Thiruvananthapuram
Healthcare | January 05, 2023

Rupala to inaugurate 29 MVUs and centralised call center in Thiruvananthapuram

MVUs will provide diagnosis treatment, vaccination, artificial insemination, minor surgical interventions, audio-visual aids and extension services to farmers/animal owners at their doorstep in far flung areas.


Yaral Pharma launches diclofenac epolamine topical system 1.3%
News | January 05, 2023

Yaral Pharma launches diclofenac epolamine topical system 1.3%

Diclofenac epolamine topical system 1.3% offers patients a non-opioid topical treatment


Biocytogen and Hansoh Pharma announce an antibody license agreement
News | January 05, 2023

Biocytogen and Hansoh Pharma announce an antibody license agreement

Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules